SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-006211
Filing Date
2017-08-08
Accepted
2017-08-08 08:01:22
Documents
63
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20170630x10q.htm 10-Q 1387431
2 EX-10.1 acrs-20170630ex10184b4f5.htm EX-10.1 35154
3 EX-31.1 acrs-20170630ex3113b57db.htm EX-31.1 17134
4 EX-31.2 acrs-20170630ex3120c0b2c.htm EX-31.2 17120
5 EX-32.1 acrs-20170630ex3215125b2.htm EX-32.1 10667
  Complete submission text file 0001558370-17-006211.txt   5657239

Data Files

Seq Description Document Type Size
6 EX-101.INS acrs-20170630.xml EX-101.INS 1322785
7 EX-101.SCH acrs-20170630.xsd EX-101.SCH 35683
8 EX-101.CAL acrs-20170630_cal.xml EX-101.CAL 39237
9 EX-101.DEF acrs-20170630_def.xml EX-101.DEF 124655
10 EX-101.LAB acrs-20170630_lab.xml EX-101.LAB 374247
11 EX-101.PRE acrs-20170630_pre.xml EX-101.PRE 257187
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 171013278
SIC: 2834 Pharmaceutical Preparations